ChiCTR2300070636 版本V1.2 版本创建时间2023/08/18 21:36:09 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300070636 

最近更新日期:

Date of Last Refreshed on:

2023-05-28 21:35:54 

注册时间:

Date of Registration:

2023-04-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

补肾活血中药结合运动疗法通过MSTN/PPAR-γ/NF-κB信号途径调节“肌肉-软骨”链治疗膝骨关节炎的作用机制研究

Public title:

Study on the mechanism of Tonifying Kidney and Promoting Blood circulation Chinese Medicine combined with exercise therapy in treating knee osteoarthritis by regulating the "muscle-cartilage" chain through MSTN/PPAR-γ/NF-κB signaling pathway

注册题目简写:

English Acronym:

研究课题的正式科学名称:

补肾活血中药结合运动疗法通过MSTN/PPAR-γ/NF-κB信号途径调节“肌肉-软骨”链治疗膝骨关节炎的作用机制研究

Scientific title:

Study on the mechanism of Tonifying Kidney and Promoting Blood circulation Chinese Medicine combined with exercise therapy in treating knee osteoarthritis by regulating the "muscle-cartilage" chain through MSTN/PPAR-γ/NF-κB signaling pathway

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

薛艳 

研究负责人:

薛艳 

Applicant:

Xue Yan 

Study leader:

Xue Yan 

申请注册联系人电话:

Applicant telephone:

+86 21 38810083

研究负责人电话:

Study leader's telephone:

+86 21 38810083

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

844523304@qq.com

研究负责人电子邮件:

Study leader's E-mail:

844523304@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

上海市养志康复医院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市松江区光星路2209号

研究负责人通讯地址:

上海市松江区光星路2209号

Applicant address:

No. 2209, Guangxing Road, Songjiang District, Shanghai

Study leader's address:

No. 2209, Guangxing Road, Songjiang District, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

201600

研究负责人邮政编码:

Study leader's postcode:

201600

申请人所在单位:

上海市养志康复医院

Applicant's institution:

Shanghai Yangzhi Rehabilitation Hospital

研究负责人所在单位:

上海市养志康复医院

Affiliation of the Leader:

Shanghai Yangzhi Rehabilitation Hospital

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2021-009-AMD-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

上海市养志康复医院(上海市阳光康复中心)伦理委员会

Name of the ethic committee:

Ethics Committee of Shanghai Yangzhi Rehabilitation Hospital (Shanghai Sunshine Rehabilitation Center)

伦理委员会批准日期:

Date of approved by ethic committee:

2023-04-11 00:00:00

伦理委员会联系人:

邵瑛琦

Contact Name of the ethic committee:

Shao Yingqi

伦理委员会联系地址:

上海市松江区光星路2209号

Contact Address of the ethic committee:

No. 2209, Guangxing Road, Songjiang District, Shanghai

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 37730011

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海市养志康复医院

Primary sponsor:

Shanghai Yangzhi Rehabilitation Hospital

研究实施负责(组长)单位地址:

上海市松江区光星路2209号

Primary sponsor's address:

No. 2209, Guangxing Road, Songjiang District, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海市

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市养志康复医院

具体地址:

上海市松江区光星路2209号

Institution
hospital:

Shanghai Yangzhi Rehabilitation Hospital

Address:

No. 2209, Guangxing Road, Songjiang District, Shanghai

经费或物资来源:

上海市科学技术委员会

Source(s) of funding:

Shanghai Municipal Science and Technology Commission

Target disease:

Knee osteoarthritis

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

明确补肾活血中药结合运动疗法通过MSTN/PPAR-γ/NF-κB信号途径调节“肌肉-软骨”链延缓膝OA的作用机制。  

Objectives of Study:

To clarify the mechanism of regulating the "muscle-cartilage" chain and delaying knee OA through MSTN/PPAR-γ/NF-κB signaling pathway of tonifying kidney and promoting blood circulation combined with exercise therapy.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

纳入符合KOA诊断标准,并且满足膝关节X线K/L评分≤2分,年龄≥50岁,签署知情同意书,依从性较高,近期未使用其他方法治疗。

Inclusion criteria

Patients who met the diagnostic criteria of KOA and met the K/L score of knee X-ray <=2 points, aged ≥50 years, signed informed consent, had high compliance, and had not been treated with other methods recently.

排除标准:

1) 非常严重的KOA患者,近期可能需要进行关节置换手术; 2) 并且合并其他严重原发性疾病者; 3) 有类风关等关节炎性疾病,或者急性滑膜炎,半月板及损伤等其他影响下肢功能的疾病; 4) 有其他危重疾病,不能配合研究的患者; 5) 本次的研究人员认为其不适合此次试验的患者; 6) 具有MRI的禁忌症。

Exclusion criteria:

1) Very severe patients with KOA may need joint replacement surgery in the near future; 2) Patients with other serious primary diseases; 3) Arthritic diseases such as wind-related diseases, or acute synovitis, meniscus and injuries and other diseases affecting lower extremity function; 4) Patients with other critical diseases who cannot cooperate with the study; 5) The researchers of this study believe that it is not suitable for the patients in this study; 6) Contraindications to MRI.

研究实施时间:

Study execute time:

From 2023-04-19 00:00:00 To 2024-04-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-04-19 00:00:00 To 2024-04-30 00:00:00  

干预措施:

Interventions:

组别:

对照组

样本量:

30

Group:

Control group

Sample size:

干预措施:

口服盐酸氨基葡萄糖片(750mg/次,2次/日,连续6周)

干预措施代码:

Intervention:

Oral glucosamine hydrochloride tablets (750mg/ time, twice a day, for 6 weeks)

Intervention code:

组别:

治疗组

样本量:

30

Group:

Treatment group

Sample size:

干预措施:

予以补肾活血中药(1袋/次,2次/日)联合等速肌力训练(3次/周,连续6周)

干预措施代码:

Intervention:

Chinese medicine for tonifying kidney and promoting blood circulation (1 bag/time, 2 times/day) combined with isokinetic strength training (3 times/week for 6 weeks)

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海市 

市(区县):

上海市 

Country:

China 

Province:

Shanghai 

City:

Shanghai 

单位(医院):

上海市养志康复医院 

单位级别:

二级 

Institution
hospital:

Shanghai Yangzhi Rehabilitation Hospital

Level of the institution:

Secondary

测量指标:

Outcomes:

指标中文名:

肌力

指标类型:

主要指标

Outcome:

Muscle strength

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

WOMAC评分

指标类型:

主要指标

Outcome:

WOMAC score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

MSTN、PPAR-γ、NF-κB、IL-1β、IL-6和TNF-α

指标类型:

次要指标

Outcome:

MSTN、PPAR-γ、NF-κB、IL-1β、IL-6 and TNF-α

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

VAS评分

指标类型:

次要指标

Outcome:

visual analog scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 50 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

利用SPSS软件产生60个随机编码表。

Randomization Procedure (please state who generates the random number sequence and by what method):

SPSS software was used to generate 60 randomly coded tables.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

仅在学术论文公开统计结果,不共享原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Publish statistical results only in academic papers, and do not share raw data

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

使用病历记录表进行数据采集,Excel进行数据管理。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Use the medical record table for data collection and Excel for data management.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-04-19 08:55:54